F-6EF 1 e665785_f6ef-abivax.htm

As filed with the Securities and Exchange Commission on September 21, 2026

Registration No. 333 -

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

_________________________________

FORM F-6

REGISTRATION STATEMENT

UNDER

THE SECURITIES ACT OF 1933 FOR AMERICAN DEPOSITARY SHARES EVIDENCED BY

AMERICAN DEPOSITARY RECEIPTS

______________

Abivax SA

(Exact name of issuer of deposited securities as specified in its charter)

______________

N/A

(Translation of issuer’s name into English)

______________

France

(Jurisdiction of incorporation or organization of issuer)

_________________________________

CITIBANK, N.A.

(Exact name of depositary as specified in its charter)

______________

388 Greenwich Street

New York, New York 10013

(877) 248-4237

(Address, including zip code, and telephone number, including area code, of depositary’s principal executive offices)

______________

Abivax LLC

880 Winter Street, Suite 1020

Waltham, MA 02451

+33 (0) 1 53 83 09 63

(Address, including zip code, and telephone number, including area code, of agent for service)

_________________________________

Copies to:

Divakar Gupta

Ryan Sansom

Minkyu Park

Cooley LLP

55 Hudson Yards

New York, New York 10001

Tel: +1 212 479-6000

Herman H. Raspé, Esq.

Jean-Claude Lanza, Esq.

Patterson Belknap Webb & Tyler LLP
1133 Avenue of the Americas
New York, New York 10036
+1 212 336-2000

_________________________________

It is proposed that this filing become effective under Rule 466:	☒ immediately upon filing.

	☐ on (Date) at (Time).

If a separate registration statement has been filed to register the deposited shares, check the following box: ☐

_________________________________

CALCULATION OF REGISTRATION FEE

Title of Each Class of
Securities to be Registered

Amount to be
Registered

Proposed Maximum

Aggregate Price Per Unit*

Proposed Maximum

Aggregate Offering Price**

Amount of

Registration Fee

American Depositary Shares (ADS(s)), each ADS representing the right to receive one (1) ordinary share of Abivax SA (the “Company”)

100,000,000 ADSs

$5.00

$5,000,000.00

$690.50

*	Each unit represents 100 ADSs.
**	Estimated solely for the purpose of calculating the registration fee. Pursuant to Rule 457(k), such estimate is computed on the basis of the maximum aggregate fees or charges to be imposed in connection with the issuance of ADSs.

This Registration Statement may be executed in any number of counterparts, each of which shall be deemed an original, and all of such counterparts together shall constitute one and the same instrument.

PART I

INFORMATION REQUIRED IN PROSPECTUS

Cross Reference Sheet

Item 1.

DESCRIPTION OF SECURITIES TO BE REGISTERED

Item Number and Caption			Location in Form of American Depositary Receipt (“Receipt”) Filed Herewith as Prospectus

1.	Name of Depositary and address of its principal executive office		Face of Receipt - Introductory Article.

2.	Title of Receipts and identity of deposited securities		Face of Receipt - Top Center.

Terms of Deposit:

	(i)	The amount of deposited securities represented by one American Depositary Share (“ADSs”)	Face of Receipt - Upper right corner.

	(ii)	The procedure for voting, if any, the deposited securities	Reverse of Receipt - Paragraphs (17) and (18).

	(iii)	The collection and distribution of dividends	Reverse of Receipt - Paragraph (15).

	(iv)	The transmission of notices, reports and proxy soliciting material	Face of Receipt - Paragraph (14); Reverse of Receipt - Paragraph (18).

	(v)	The sale or exercise of rights	Reverse of Receipt – Paragraphs (15) and (17).

	(vi)	The deposit or sale of securities resulting from dividends, splits or plans of reorganization	Face of Receipt - Paragraphs (3) and (6); Reverse of Receipt - Paragraphs (15) and (17).

	(vii)	Amendment, extension or termination of the deposit agreement	Reverse of Receipt - Paragraphs (23) and (24) (no provision for extensions).

	(viii)	Rights of holders of Receipts to inspect the transfer books of the Depositary and the list of holders of ADSs	Face of Receipt - Paragraph (14).

I-1

Item Number and Caption			Location in Form of American Depositary Receipt (“Receipt”) Filed Herewith as Prospectus

	(ix)	Restrictions upon the right to deposit or withdraw the underlying securities	Face of Receipt – Paragraphs (2), (3), (4), (6), (7), (8), (9) and (10); Reverse of Receipt – Paragraph (25).

	(x)	Limitation upon the liability of the Depositary	Face of Receipt - Paragraphs (8) and (12); Reverse of Receipt - Paragraphs (15), (16), (18), (19), (20), (21) and (25).

3.	Fees and charges which may be imposed directly or indirectly on holders of ADSs		Face of Receipt - Paragraph (11).

Item 2.		AVAILABLE INFORMATION	Face of Receipt - Paragraph (14).

The Company is subject to the periodic reporting requirements of the United States Securities Exchange Act of 1934, as amended, and, accordingly, files certain reports with, and submits certain reports to, the United States Securities and Exchange Commission (the “Commission”). These reports can be retrieved from the Commission’s internet website (www.sec.gov), and can be inspected and copied at the public reference facilities maintained by the Commission at 100 F Street, N.E., Washington D.C. 20549.

I-2

PROSPECTUS

The Prospectus consists of the form of American Depositary Receipt included as Exhibit A to the Deposit Agreement filed as Exhibit (a) to this Registration Statement on Form F-6 and is incorporated herein by reference.

I-3

PART II

INFORMATION NOT REQUIRED IN PROSPECTUS

Item 3.

EXHIBITS

(a)

Deposit Agreement, dated as of October 24, 2023, by and among Abivax SA (the “Company”), Citibank, N.A., as depositary (the “Depositary”), and all Holders and Beneficial Owners of American Depositary Shares issued thereunder (“Deposit Agreement”). ^___ Filed herewith as Exhibit (a).

(b)(i)

At-the-Market Letter Agreement, dated as of December 10, 2024, by and between the Company and the Depositary. ^___ Filed herewith as Exhibit (b)(i).

(b)(ii)

Omnibus Restricted ADS Letter Agreement, dated as of December 3, 2025, by and between the Company and the Depositary. ^___ Filed herewith as Exhibit (b)(ii).

(b)(iii)

Affiliate and Restricted Securities Series Supplemental Letter Agreement, dated as of December 3, 2025, by and between the Company and the Depositary. ^___ Filed herewith as Exhibit (b)(iii).

(b)(iv)

Royalty Certificate Letter Agreement, dated as of May 7, 2026, by and between the Company and the Depositary. ^___ Filed herewith as Exhibit (b)(iv).

(c)

Every material contract relating to the deposited securities between the Depositary and the issuer of the deposited securities in effect at any time within the last three years. ^___ None.

(d)

Opinion of counsel for the Depositary as to the legality of the securities to be registered. ^___ Filed herewith as Exhibit (d).

(e)

Certificate under Rule 466. ^___ Filed herewith as Exhibit (e).

(f)

Powers of Attorney for certain officers and directors and the authorized representative of the Company. ^___ Set forth on the signature pages hereto.

II-1

Item 4.

UNDERTAKINGS

(a)

The Depositary undertakes to make available at the principal office of the Depositary in the United States, for inspection by holders of ADSs, any reports and communications received from the issuer of the deposited securities which are both (1) received by the Depositary as the holder of the deposited securities, and (2) made generally available to the holders of the underlying securities by the issuer.

(b)

If the amount of fees charged is not disclosed in the prospectus, the Depositary undertakes to prepare a separate document stating the amount of any fee charged and describing the service for which it is charged and to deliver promptly a copy of such fee schedule without charge to anyone upon request. The Depositary undertakes to notify each registered holder of an ADS thirty (30) days before any change in the fee schedule.

II-2

SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, as amended, Citibank, N.A., acting solely on behalf of the legal entity created by the Deposit Agreement, dated as of October 24, 2023, by and among Abivax SA, Citibank, N.A., as depositary, and all Holders and Beneficial Owners of American Depositary Shares to be issued thereunder, certifies that it has reasonable grounds to believe that all the requirements for filing on Form F-6 are met and has duly caused this Registration Statement on Form F-6 to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of New York, State of New York, on the 21st day of September 2026.

	Legal entity created by the Deposit Agreement under which the American Depositary Shares registered hereunder are to be issued, each American Depositary Share representing the right to receive one (1) ordinary share of Abivax SA

	CITIBANK, N.A., solely in its capacity as Depositary

	By:	/s/ Leslie DeLuca
		Name: Leslie DeLuca
		Title: Attorney-in-Fact

II-3

SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, as amended, Abivax SA certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form F-6 and has duly caused this Registration Statement on Form F-6 to be signed on its behalf by the undersigned thereunto duly authorized, in Waltham, Massachusetts, on September 21, 2026.

	ABIVAX SA

	By:	/s/ Marc de Garidel
		Name: Marc de Garidel
		Title: Chief Executive Officer and Director

II-4

POWERS OF ATTORNEY AND SIGNATURES

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints each of Marc de Garidel and Didier Blondel to act as his/her true and lawful attorney-in-fact and agent, with full power of substitution, for him/her and in his/her name, place and stead, in any and all such capacities, to sign any and all amendments, including post-effective amendments, and supplements to this Registration Statement, and to file the same, with all exhibits thereto and other documents in connection therewith, with the United States Securities and Exchange Commission, granting unto said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as s/he might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, or his/her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement on Form F-6 has been signed by the following persons in the capacities and on the dates indicated.

Name	Title	Date

/s/ Marc de Garidel	Chief Executive Officer and Director	September 21, 2026
Marc de Garidel	(Principal Executive Officer)

/s/ Didier Blondel	Chief Financial Officer and Board Secretary	September 21, 2026
Didier Blondel	(Principal Financial Officer and Principal Accounting Officer)

/s/ Sylvie Grégoire	Chair of the Board	September 21, 2026
Sylvie Grégoire

/s/ Corinna zur Bonsen-Thomas	Director	September 21, 2026
Corinna zur Bonsen-Thomas

/s/ June Lee	Director	September 21, 2026
June Lee

II-5

Name	Title	Date

/s/ Troy Ignelzi	Director
Troy Ignelzi		September 21, 2026

/s/ Camilla Soenderby	Director
Camilla Soenderby		September 21, 2026

/s/ Dominik Höchli	Director
Dominik Höchli		September 21, 2026

II-6

SIGNATURE OF AUTHORIZED REPRESENTATIVE OF THE REGISTRANT IN THE UNITED STATES

Pursuant to the Securities Act of 1933, as amended, the undersigned, the duly authorized representative in the United States of America has signed this Registration Statement on Form F-6 in Waltham, Massachusetts, on September 21, 2026.

	/s/ Marc de Garidel
	Name: Marc de Garidel

II-7

Index to Exhibits

Exhibit	Document	Sequentially Numbered Page

(a)	Deposit Agreement
(b)(i)	At-the-Market Letter Agreement
(b)(ii)	Omnibus Restricted ADS Letter Agreement
(b)(iii)	Affiliate and Restricted Securities Series Supplemental Letter Agreement
(b)(iv)	Royalty Certificate Letter Agreement
(d)	Opinion of counsel to the Depositary
(e)	Rule 466 Certificate

II-8